Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Galectin Therapeutics Inc (GALT) USD0.001

Sell:$3.55 Buy:$4.56 Change: $0.11 (2.36%)
NASDAQ:1.04%
Market closed |  Prices as at close on 17 May 2019 | Switch to live prices |
Sell:$3.55
Buy:$4.56
Change: $0.11 (2.36%)
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
Market closed |  Prices as at close on 17 May 2019 | Switch to live prices |
Sell:$3.55
Buy:$4.56
Change: $0.11 (2.36%)
Market closed |  Prices as at close on 17 May 2019 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.

Contact details

Address:
4960 Peachtree Industrial Blvd Ste 240
BERKELEY LAKE
30071-1580
United States
Telephone:
+1 (678) 6203186
Website:
www.galectintherapeutics.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GALT
ISIN:
US3632252025
Market cap:
$207.45 million
Shares in issue:
45.59 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Harold Shlevin
    President, Chief Executive Officer, Chief Operating Officer
  • Jack Callicutt
    Chief Financial Officer, Secretary
  • Eliezer Zomer
    Executive Vice President - Manufacturing and Product Development
  • Adam Allgood
    Executive Director of Clinical Development
  • J. Rex Horton
    Executive Director - Regulatory Affairs and Quality Assurance

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.